Translational Toxicology and Therapeutics

Windows of Developmental Susceptibility in Reproduction and Cancer
 
 
Wiley (Verlag)
  • erschienen am 10. November 2017
  • |
  • 784 Seiten
 
E-Book | ePUB mit Adobe DRM | Systemvoraussetzungen
978-1-119-02362-3 (ISBN)
 
Written by leading research scientists, this book integrates current knowledge of toxicology and human health through coverage of environmental toxicants, genetic / epigenetic mechanisms, and carcinogenicity.
* Provides information on lifestyle choices that can reduce cancer risk
* Offers a systematic approach to identify mutagenic, developmental and reproductive toxicants
* Helps readers develop new animal models and tests to assess toxic impacts of mutation and cancer on human health
* Explains specific cellular and molecular targets of known toxicants operating through genetic and epigenetic mechanisms
weitere Ausgaben werden ermittelt
MICHAEL D. WATERS, PhD, is an independent consultant with over 40 years of toxicology and toxicogenomics research experience at the EPA, at NIH/NIEHS and in the private sector. He has held adjunct professorships in toxicology and pharmacology at both the University of North Carolina and Duke University.
CLAUDE L. HUGHES, MD, PhD, is an Executive Director in the Therapeutic Science and Strategy Unit at QuintilesIMS. He is also an Adjunct Professor at North Carolina State University, and Wake Forest University as well as a Consulting Professor at Duke University Medical Center.
  • Title Page
  • Copyright
  • List of Contributors
  • Part One: Introduction: The Case for Concern about Mutation and Cancer Susceptibility during Critical Windows of Development and the Opportunity to Translate Toxicology into a Therapeutic Discipline
  • Chapter 1: What Stressors Cause Cancer and When?
  • 1.1 Introduction
  • 1.2 What Stressors Cause Cancer and When?
  • 1.3 Relevance of Circulating Cancer Markers
  • 1.4 Potential Cancer Translational Toxicology Therapies
  • 1.5 Modeling and the Future
  • References
  • Chapter 2: What Mutagenic Events Contribute to Human Cancer and Genetic Disease?
  • 2.1 Introduction
  • 2.2 Genetic Damage from Environmental Agents
  • 2.3 Testing for Mutagenicity and Carcinogenicity
  • 2.4 Predictive Toxicogenomics for Carcinogenicity
  • 2.5 Germ Line Mutagenicity and Screening Tests
  • 2.6 Reproductive Toxicology Assays in the Assessment of Heritable Effects
  • 2.7 Assays in Need of Further Development or Validation
  • 2.8 New Technologies
  • 2.9 Endpoints Most Relevant to Human Genetic Risk
  • 2.10 Worldwide Regulatory Requirements for Germ Cell Testing
  • 2.11 Conclusion
  • Acknowledgments
  • References
  • Chapter 3: Developmental Origins of Cancer
  • 3.1 Introduction
  • 3.2 Current Trends in Childhood Cancer
  • 3.3 Potential Mechanisms of Prenatal Cancer Induction
  • 3.4 Ontogeny of Xenobiotic Metabolizing Enzymes and DNA Repair Systems
  • 3.5 The Developmental Origins of Health and Disease (DOHaD) Theory
  • 3.6 Epigenetic Regulation during Development
  • 3.7 Mechanisms of Cancer in Offspring from Paternal Exposures
  • 3.8 Parental Exposures Associated with Cancer in Offspring
  • 3.9 Models for the Developmental Origins of Selected Cancers
  • 3.10 Public Health Agencies' Views on Prenatal Exposures and Cancer Risk
  • 3.11 Conclusions
  • Acknowledgment
  • References
  • Chapter 4: The Mechanistic Basis of Cancer Prevention
  • 4.1 Introduction
  • 4.2 A Mechanistic Approach
  • 4.3 Preventing Cancer Attributable to Known Carcinogens
  • 4.4 Prevention Involving Complex Risk Factors
  • 4.5 Prevention Independent of Causative Agents or Risk Factors
  • 4.6 Conclusion
  • References
  • Part Two: Exposures that Could Alter the Risk of Cancer Occurrence, and Impact Its Indolent or Aggressive Behavior and Progression Over Time
  • Chapter 5: Diet Factors in Cancer Risk
  • 5.1 Introduction
  • 5.2 Obesity
  • 5.3 Macronutrients
  • 5.4 Micronutrients
  • 5.5 Phytochemicals
  • 5.6 Conclusions
  • References
  • Chapter 6: Voluntary Exposures: Natural Herbals, Supplements, and Substances of Abuse â?? What Evidence Distinguishes Therapeutic from Adverse Responses?
  • 6.1 Introduction
  • 6.2 Summary and Conclusions
  • References
  • Chapter 7: Voluntary Exposures: Pharmaceutical Chemicals in Prescription and Over-the-Counter Drugs â?? Passing the Testing Gauntlet
  • 7.1 Introduction
  • 7.2 Testing of New Drug Entities for Genotoxicity
  • 7.3 Relationship between Genotoxicity Testing and Rodent Carcinogenicity
  • 7.4 Can Drug-Induced Human Cancer Be Predicted?
  • 7.5 What Can Rodent Carcinogenicity Tell Us about Human Cancer Risk?
  • 7.6 Genotoxicity Prediction Using â??Traditionalâ?? In Silico Approaches
  • 7.7 Covalent versus Noncovalent DNA Interaction
  • 7.8 Use of New Technologies to Predict Toxicity and Cancer Risk: High-Throughput Methods
  • 7.9 Transcriptomics
  • 7.10 Single-Nucleotide Polymorphisms (SNPs)
  • 7.11 Conclusions
  • Appendix A
  • References
  • Chapter 8: Children's and Adult Involuntary and Occupational Exposures and Cancer
  • 8.1 Introduction
  • 8.2 Occupational Exposures and Cancer
  • 8.3 Environmental Exposures and Cancer
  • 8.4 Conclusions and Future Perspectives
  • References
  • Part Three: Geneâ??Environment Interactions
  • Chapter 9: Ethnicity, Geographic Location, and Cancer
  • 9.1 Introduction
  • 9.2 Classification of Cancer
  • 9.3 Ethnicity and Cancer
  • 9.4 Geographic Location and Cancer
  • 9.5 Ethnicity, Geographic Location, and Lung Cancer
  • 9.6 Common Cancers in China
  • 9.7 Cancer Risk Factors and Prevention
  • References
  • Chapter 10: Dietary/Supplemental Interventions and Personal Dietary Preferences for Cancer: Translational Toxicology Therapeutic Portfolio for Cancer Risk Reduction
  • 10.1 Introduction
  • 10.2 Gene Expression and Epigenetics
  • 10.3 Environmental Lifestyle Factors Affecting Cancer Prevention and Risk
  • 10.4 Dietary Patterns
  • 10.5 Complementary and Integrative Oncology Interventions/Restorative Therapeutics
  • 10.6 Special and Alternative Diets
  • 10.7 Popular Anticancer Diets
  • 10.8 Conclusion
  • Acknowledgment
  • References
  • Chapter 11: Social Determinants of Health and the Environmental Exposures: A Promising Partnership
  • 11.1 Introduction
  • 11.2 Social Determinants of Health
  • 11.3 Conclusions: Social Determinants of Health and Windows of Susceptibility
  • Acknowledgments
  • References
  • Part Four: Categorical and Pleiotropic Nonmutagenic Modes of Action of Toxicants: Causality
  • Chapter 12: Bisphenol A and Nongenotoxic Drivers of Cancer
  • 12.1 Introduction
  • 12.2 Dosing
  • 12.3 Receptor-mediated Signaling
  • 12.4 Epigenetic Reprogramming
  • 12.5 Oxidative Stress
  • 12.6 Inflammation and Immune Response
  • 12.7 BPA-Induced Carcinogenesis
  • 12.8 Fresh Opportunities in BPA Research
  • References
  • Chapter 13: Toxicoepigenetics and Effects on Life Course Disease Susceptibility
  • 13.1 Introduction to the Field of Toxicoepigenetics
  • 13.2 Exposures that Influence the Epigenome
  • 13.3 Intergenerational Exposures and Epigenetic Effects
  • 13.4 Special Considerations and Future Directions for the Field of Toxicoepigenetics
  • 13.5 Future Directions
  • 13.6 Conclusions
  • Acknowledgments
  • References
  • Chapter 14: Tumor-Promoting/Associated Inflammation and the Microenvironment: A State of the Science and New Horizons
  • 14.1 Introduction
  • 14.2 The Immune System
  • 14.3 Prioritized Chemicals
  • 14.4 Experimental Models of Carcinogenesis through Inflammation and Immune System Deregulation
  • 14.5 Antioxidants and Translational Opportunities
  • 14.6 Tumor Control of the Microenvironment
  • Acknowledgments
  • References
  • Chapter 15: Metabolic Dysregulation in Environmental Carcinogenesis and Toxicology
  • 15.1 Introduction
  • 15.2 Metabolic Reprogramming and Dysregulation in Cancer
  • 15.3 Moonlighting Functions
  • 15.4 Cancer Metabolism in Context
  • 15.5 Dual Roles for Metabolism in Both the Generation and Mitigation of Cellular Stress
  • 15.6 Models of Carcinogenesis
  • 15.7 Potential Metabolic Targets for Environmental Exposures
  • 15.8 Metabolic Changes Associated with Exposures to Selected Agents
  • 15.9 A Conceptual Overview of Traditional and Emerging Toxicological Approaches to the Problem of Cancer Metabolism: Implications for Future Research
  • 15.10 The Nosology of Cancer and Cancer Development
  • 15.11 Discussion
  • Acknowledgments
  • References
  • Part Five: Biomarkers for Detecting Premalignant Effects and Responses to Protective Therapies during Critical Windows of Development
  • Chapter 16: Circulating Molecular and Cellular Biomarkers in Cancer
  • 16.1 Introduction
  • 16.2 Proteins in Body Fluids: Potential Biomarkers
  • 16.3 Circulating Cell-Free Nucleic Acids
  • 16.4 Extracellular Vesicles: General Features
  • 16.5 Circulating Tumor Cells
  • 16.6 Conclusions
  • References
  • Chapter 17: Global Profiling Platforms and Data Integration to Inform Systems Biology and Translational Toxicology
  • 17.1 Introduction
  • 17.2 Global Omics Profiling Platforms
  • 17.3 High-Throughput Bioactivity Profiling
  • 17.4 Biomarkers
  • 17.5 Exposomics
  • 17.6 Bioinformatics to Support and Data Integration and Multiomics Efforts
  • 17.7 Data Integration: Multiomics and High-Dimensional Biology Efforts
  • 17.8 Conclusion
  • References
  • Chapter 18: Developing a Translational Toxicology Therapeutic Portfolio for Cancer Risk Reduction
  • 18.1 Introduction
  • 18.2 The Identification of Novel Predictors of Adverse Events
  • 18.3 Proof of Principle Toxgnostics
  • 18.4 Proposed Protocol
  • 18.5 Fiscal Matters
  • 18.6 The Future of Toxgnostics
  • References
  • Chapter 19: Ethical Considerations in Developing Strategies for Protecting Fetuses, Neonates, Children, and Adolescents from Exposures to Hazardous Environmental Agents
  • 19.1 Introduction
  • 19.2 What Is Ethics?
  • 19.3 Ethical Considerations for Strategies Used to Protect Fetuses, Neonates, Children, and Adolescents from Exposures to Harmful Environmental Agents
  • 19.4 Research with Human Participants
  • 19.5 Conclusion
  • References
  • Index

1
What Stressors Cause Cancer and When?


Claude L. Hughes1,2,3 and Michael D. Waters4

1Therapeutic Science and Strategy Unit QuintilesIMS Inc., Morrisville, NC, USA

2Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC, USA

3Department of Mathematics, North Carolina State University, Raleigh, NC, USA

4Michael Waters Consulting USA, Hillsborough, NC, USA

1.1 Introduction


Translational biomedical research seeks to move laboratory findings based on models (in silico, in vitro, and in vivo) into human clinical trials to more expeditiously develop specific therapeutics, and then back again to the laboratory to inform future discovery [1]. From the background of developmental toxicology, it is well known that toxicant exposures may affect critical events in reproductive development, ranging from early primordial germ cell determination to gonadal differentiation, gametogenesis, external genitalia, or signaling events regulating sexual behavior. Translational genetic toxicology takes advantage of this developmental perspective to assess potential germ line mutagenesis or to study the potential for cancer in the fetus or offspring or the adult as the result of environmental exposures. Translational toxicology must strive to identify applicable therapeutics that can safely and effectively identify and help to mitigate potential harm from natural as well as anthropogenic environmental exposures.

Human exposures to chemicals, physical agents, and social factors are inevitable, thus the human fetus and the adult are subject to exposures and effects that can have lifelong consequences. Particularly, during dynamic developmental intervals described as "critical windows of susceptibility," exposures may have robust and durable effects that drive long-term health outcomes, including metabolism, functional status of organ systems, and cancer risks [2]. These same dynamic developmental intervals should be seen as "critical windows of responsivity" during which favorable/protective interventions should also be highly impactful offering potential durable reduction in risks of multiple adverse health outcomes, including cancers. To reduce the lifelong occurrence of preventable cancers, timely protective interventions during "critical windows" should include not only minimization of untoward voluntary exposures and substances of abuse but also active use of protective generally recognized as safe (GRAS) interventions/therapies, including nutritional, dietary supplementation, or well-established/repurposed and/or generally recognized as safe and effective (GRASE) pharmaceutical drugs.

This introductory chapter will promote the elucidation of cell stage, life stage, and lifestyle knowledge of specific cellular and molecular targets of known developmental toxicants, develop a systematic integrated approach to the identification of mutagenic and reproductive toxicants, and discuss sensitive, specific, and predictive animal models, to include minimally invasive surrogate markers, and/or in vitro tests to assess reproductive system function during embryonic, postnatal, and adult life. It will argue that integrated testing strategies will be required to account for the many mechanisms associated with development that occur in vivo. A key organizing principle used throughout this book is to consider how exposures that incur risk or other exposures/life events that may reduce risk during particular windows of susceptibility/developmental transitions, and thereby impact cancer occurrence.

In consideration of any cause-effect relationship, typically one thinks of the simple questions: Who, what, where, when, and how? Admittedly, "How?" questions are generally the most difficult because that understanding is a synthesis of potentially causal pathways. We aim to consider that the "Who?" and "When?" questions could be seen as people being exposed at different intervals across their respective life spans. Thus, in addition to information regarding what exposures occur that influence cancer occurrence, what is and is not known about exposures to those agents during life span intervals such as childhood, adolescence, across the broader life span, and/or late in life? Assessment of such timing of exposure with cancer outcomes seems to be a critical element if we aim to develop protective interventional strategies. In other words, whether we aim to reduce exposures or advocate protective lifestyle or therapeutic interventions, we must know when those interventions would most effectively impact later cancer outcomes.

Although there are differences between human development and that of laboratory animal models, developmental models have been extremely useful in assessing risks for key human reproductive and developmental processes. Some of these models will be discussed in Chapters 2 and 3. However, such systems have not been fully integrated with models to assess germ line mutagenesis or to study the potential for cancer in the fetus or offspring as the result of environmental exposures. Again, Chapters 2 and 3 will address current proposals for experimental animal test system integration.

To delve into the impact of exposures during "windows of susceptibility/responsivity," we must take into account the unique susceptibilities of the fetus. Relatively, new information suggests that some widely held notions relevant to fetal exposures are incorrect [3]. Thus, we now know that amniotic fluid can be reabsorbed into the fetal circulation by fetal swallowing as well as via the fetal intramembranous pathway. The latter pathway is thought to be the most important mechanism for the resorption of toxicants, such as ethanol, into the fetal circulation [4]. Together with swallowing, this is a recycling system, through which toxic substances are excreted into the amniotic fluid and reabsorbed into the fetal circulation, thus extending the duration of each exposure [5,6]. This and other information relevant to fetal exposure in utero will be discussed in Chapter 8.

1.1.1 General Information about Cancer


Each year the American Cancer Society estimates the number of new cancer cases and deaths that will occur in the United States that year. In 2016, a total of 1,685,210 new cancer cases were expected to be diagnosed and about 595,690 cancer deaths were projected to occur in the United States [7]. Among children up to 14 years of age, an estimated 10,380 new cancer cases were expected to occur in 2016.

Population-based cancer registration began in the United States in 1975. Since then, childhood cancer incidence rates have increased by 0.6% per year. In 2016, 1250 cancer deaths were expected to occur among children. Cancer is the second leading cause of death in children ages 1-14 years, exceeded only by accidents. Childhood cancer death rates declined a total of 66% from 1969 (6.5 per 100,000) to 2012 (2.2 per 100,000). According to the American Society, this was largely due to improvements in treatment and high rates of participation in clinical trials. From 2003 to 2012, the rate of cancer-caused deaths in children declined by 1.3% per year.

Siegel et al. [8] reported that during the period 2006-2010, the then most recent 5 years for which there were data, the delay-adjusted cancer incidence rates declined by 0.6% per year in men and were stable in women. At the same time, cancer death rates decreased by 1.8% per year in men and by 1.4% per year in women. The rate of combined cancer deaths per 100,000 populations has declined continuously for two decades, from a peak of 215.1 in 1991 to 171.8 in 2010. The 20% decline during this time period equates to the avoidance of 1,340,400 cancer deaths (952,700 among men and 387,700 among women). Siegel et al. reported that the magnitude of the decline in cancer death rates varies substantially by age, race, and sex, with no decline among white women of 80 years of age and older to a 55% decline among black men 40-49 years of age. Remarkably, black men experienced the largest drop within every 10-year age group. The authors noted that progress could be accelerated by applying cancer control knowledge across all segments of the population [8].

While the severity of cancers is often measured in number of deaths, the number of years of life lost (YLL) may be a more appropriate indicator of impact on society [9]. These authors calculated the YLL of adult cancers in Norway for 2012 and for the prior 15-year period. Their results showed that cancer deaths in Norway in 2012 represented 25.8% of all adult deaths (28.7% in men and 23.1% in women). Cancer deaths represented 35.2% of all YLL, with a 5.0% higher fraction in females than in males (32.8% in men and 37.8% in women) [9].

The etiology of cancer is generally thought to be the product of gene and environmental interactions. Environmental exposures are typically low and to mixtures of constituents that occur indoors and outdoors. Goodson et al. hypothesized that low-dose exposures to mixtures of chemicals in the environment may be combining to contribute to environmental carcinogenesis [10]. They reviewed 11 hallmark phenotypes of cancer, with multiple priority target sites for disruption in each area and prototypical chemical disruptors for all targets. Dose-response characterizations and evidence of low-dose effects and cross-hallmark effects for all targets and chemicals were considered. In total, 85 examples of chemicals were reviewed...

Dateiformat: EPUB
Kopierschutz: Adobe-DRM (Digital Rights Management)

Systemvoraussetzungen:

Computer (Windows; MacOS X; Linux): Installieren Sie bereits vor dem Download die kostenlose Software Adobe Digital Editions (siehe E-Book Hilfe).

Tablet/Smartphone (Android; iOS): Installieren Sie bereits vor dem Download die kostenlose App Adobe Digital Editions (siehe E-Book Hilfe).

E-Book-Reader: Bookeen, Kobo, Pocketbook, Sony, Tolino u.v.a.m. (nicht Kindle)

Das Dateiformat EPUB ist sehr gut für Romane und Sachbücher geeignet - also für "fließenden" Text ohne komplexes Layout. Bei E-Readern oder Smartphones passt sich der Zeilen- und Seitenumbruch automatisch den kleinen Displays an. Mit Adobe-DRM wird hier ein "harter" Kopierschutz verwendet. Wenn die notwendigen Voraussetzungen nicht vorliegen, können Sie das E-Book leider nicht öffnen. Daher müssen Sie bereits vor dem Download Ihre Lese-Hardware vorbereiten.

Weitere Informationen finden Sie in unserer E-Book Hilfe.


Download (sofort verfügbar)

194,99 €
inkl. 19% MwSt.
Download / Einzel-Lizenz
ePUB mit Adobe DRM
siehe Systemvoraussetzungen
E-Book bestellen

Unsere Web-Seiten verwenden Cookies. Mit der Nutzung dieser Web-Seiten erklären Sie sich damit einverstanden. Mehr Informationen finden Sie in unserem Datenschutzhinweis. Ok